ClinicalTrials.gg
CompletedNCT05699460Updated Jul 27, 2026

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

An observational study in Parkinson's Disease, Multiple System Atrophy, Parkinson Variant and Multiple System Atrophy, sponsored by AskBio Inc. Completed at 11 sites in 2 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by AskBio Inc (part of Bayer) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
73
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Parkinson Disease by Bayer — 6 open to participants now, 8 under way, 1 of them phase 3. Parkinson Disease · Bayer.

Started
2022
with 1 other
Observational
5 of 12
3 open now
Registered
5th of 12
by date

Among the 12 studies in Parkinson Disease by Bayer, this one is one of 2 that started in 2022, is one of 5 observational ones, and was the 5th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 12 studies in Parkinson Disease by Bayer are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Parkinson Disease by Bayer, or all of them as a file.
02

Study summary

The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.

03

Conditions studied

  • Parkinson's Disease
  • Multiple System Atrophy, Parkinson Variant
  • Multiple System Atrophy

Keywords

  • MSA
  • MSA-P
  • PD
  • Observational
  • Natural History
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will have a diagnosis of early Parkinson's disease OR possible or probably MSA-P

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Idiopathic PD
  • Diagnosis of MSA-P
  • One to six years from clinical diagnosis of PD
  • Less than 4 years from clinical diagnosis of MSA with expected survival >3 years
  • Stable medication regimen
  • Ability to walk with or without an assistive device

Exclusion criteria

Exclusion Criteria:

  • Movement disorder due to known cerebrovascular disease, brain tumor, trauma, exposure to parkinsonian-linked toxicants or other neurological diseases
  • Presence of dementia, psychosis, substance abuse or poorly controlled depression
  • Prior brain surgery (i.e. deep brain stimulation) or other brain imaging abnormalities
  • History of cancer or poorly controlled medical conditions
  • Receiving an drug

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
73 participants (actual)
Patient registry
No

Groups and cohorts

  • Early Parkinson's disease

    Other: This is an observational study.

  • Possible or Probable MSA-P

    Other: This is an observational study.

Interventions

  • OtherThis is an observational study.

    This is an observational study.

06

What researchers measure

Primary outcomes

  1. Motor symptoms as assessed by the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Change from baseline in the MDS-UPDRS. The MDS-UPDRS contains 4 subscales: Part I, non-motor aspects of experiences of daily living (13 items); Part II, motor aspects of experiences of daily living (13 items); Part III, motor examination (33 scores based on 18 items); Part IV, motor complications (6 items). The rating for each item, or sub-item, is from 0 (normal) to 4 (severe). The total score for each Part is obtained from the sum of the corresponding item scores.

    Time frame: 18 months

  2. MSA symptoms/signs as assessed by the Unified Multiple System Atrophy Rating Scale (UMSARS)

    Change from baseline in the Unified Multiple System Atrophy Rating Scale (UMSARS) and compared to placebo. UMSARS total scores range from 0-104 points with higher scores indicating greater severity of impairment.

    Time frame: 18 Months

Secondary outcomes

  1. Change in the quality of life as measured by Parkinson's Disease Questionnaire (PDQ-39)

    Change from baseline in the Parkinson's Disease Questionnaire (PDQ-39). PDQ-39 is a self-reported 39-item questionnaire designed to measure health related quality of life in Parkinson's Disease patients. It provides scores in 8 domains: mobility, activities of daily living, emotions, stigma, social support, cognitive function, bodily discomfort and communication, as well as a summary index score for quality of life.

    Time frame: 18 months

  2. Change in the quality of life as measured by Multiple System Atrophy Quality of Life (MSA-QoL)

    Change from baseline in the Multiple System Atrophy Quality of Life (MSA-QoL) scale. MSA-QoL is a self-reported questionnaire that measures MSA impact in day to day activities. Scale consists of 40 items with a five response option format (0 - no problem to 4 extreme problem) and a "not applicable" response option.

    Time frame: 18 months

07

Study locations

11 sites
  • University of California Irvine
    Irvine, California 92697, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Ohio Health Research Institute
    Columbus, Ohio 43214, United States
  • OHSU Parkinson Center & Movement Disorders Program
    Portland, Oregon 97239, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Zespol Poradni Specjalistycznych - Botaniczna 3 Poradnia Neurologiczna Szpital Uniwersytecki w Krakowie
    Krakow, Lesser Poland Voivodeship, Poland
  • Specjalistyczna Praktyka Lekarska, Prof. Grzegorz Opala
    Katowice, Poland
  • Mazowiecki Szpital Bródnowski w Warszawie, Oddział Neurologii
    Warsaw, Poland
  • Samodzielny Publiczny Szpital Kliniczny im. prof. Witolda Orłowskiego, Oddział Neurologii i Epileptologii
    Warsaw, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Nov 2025, 37 months.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 37 months is close to that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Jan 26, 2023
StartActual
Sep 29, 2022
Primary completionActual
Nov 4, 2025
CompletionActual
Nov 4, 2025
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05699460
Lead sponsor
AskBio Inc
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Sep 29, 2022
Primary completion
Nov 4, 2025
Completion
Nov 4, 2025
Last update
Jul 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion